scispace - formally typeset
N

Niaz Mahmood

Researcher at McGill University

Publications -  32
Citations -  1013

Niaz Mahmood is an academic researcher from McGill University. The author has contributed to research in topics: DNA methylation & Cancer. The author has an hindex of 11, co-authored 31 publications receiving 642 citations. Previous affiliations of Niaz Mahmood include Bangladesh Jute Research Institute & University of Manitoba.

Papers
More filters
Journal ArticleDOI

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

TL;DR: The components of the PA system show altered expression patterns in several common malignancies, which have identified them as ideal diagnostic, prognostic, and therapeutic targets to reduce cancer-associated morbidity and mortality.
Journal ArticleDOI

Food Processing and Maillard Reaction Products: Effect on Human Health and Nutrition

TL;DR: In this review, how food processing effects MRP formation in some of the very common foods is summarized.
Journal ArticleDOI

DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications.

TL;DR: The current state of knowledge on the different classes of DNA methylation “readers” identified thus far are described along with their normal biological functions, how they are dysregulated in cancer is described, and the various anti-cancer therapies that are currently being developed and evaluated for targeting these proteins are discussed.
Journal ArticleDOI

Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications

TL;DR: Gene expression analyses validated the ability of SAM to decrease the expression of several key genes implicated in cancer progression and metastasis in both cell lines and breast tumor xenografts and provided compelling evidence to evaluate the therapeutic potential of methylating agents like SAM in patients with breast cancer to reduce cancer-associated morbidity and mortality.